{"entity":{"id":"thygenext-thyramir","kind":"drug","name":"ThyGeNEXT and ThyraMIR v2","aka":["ThyGeNEXT","ThyraMIR","Interpace multiplatform thyroid test"],"tldr":"A pair of tests on a thyroid nodule needle sample, one reading DNA and RNA fusions and one reading small regulatory RNAs, to judge whether an uncertain nodule is likely to be cancer.","summary":"Interpace Biosciences describes ThyGeNEXT as a DNA mutation panel plus an RNA fusion panel (ALK, BRAF, NTRK, PPARG, RET, THADA) and mRNA markers (NKX2-1, PAX8, TBP, USP33), billed under PLA code 0245U, \"mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers\"; ThyraMIR v2 \"analyzes microRNA signatures\". In a multicentre study of indeterminate nodules the combined test had 95 per cent sensitivity, 90 per cent specificity, a 97 per cent negative predictive value and a 75 per cent positive predictive value (Lupo 2020).","status":"established","asOf":"2026-11-04","links":[{"label":"Interpace: ThyGeNEXT and ThyraMIR","url":"https://thygenext-thyramir.com/"}],"tags":["test","rna"],"related":["thyroseq","afirma"],"cancers":["thyroid"],"sections":[],"technologies":["thyroid-fna-molecular"],"targets":[],"drugs":[],"companies":["interpace-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-lupo-multiplatform-thyroid-nodule-diagn-cytopathol-2020"],"journals":[],"dependsOn":[],"notes":[],"brand":"ThyGeNEXT / ThyraMIR","modality":"DNA mutation, RNA fusion and microRNA classifier (thyroid nodule aspirates)","mechanism":"ThyGeNEXT sequences DNA mutations, RNA fusions and four mRNA markers; ThyraMIR v2 measures a microRNA signature; together they classify an indeterminate thyroid nodule.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/thygenext-thyramir/","neighbours":{"drug":[{"id":"afirma","kind":"drug","name":"Afirma Genomic Sequencing Classifier","route":"/drugs/afirma/"},{"id":"thyroseq","kind":"drug","name":"ThyroSeq v3 Genomic Classifier","route":"/drugs/thyroseq/"}],"cancer":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"technology":[{"id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/"}],"company":[{"id":"interpace-biosciences","kind":"company","name":"Interpace Biosciences","route":"/companies/interpace-biosciences/"}],"paper":[{"id":"paper-lupo-multiplatform-thyroid-nodule-diagn-cytopathol-2020","kind":"paper","name":"Multiplatform molecular test performance in indeterminate thyroid nodules","route":"/key-papers/paper-lupo-multiplatform-thyroid-nodule-diagn-cytopathol-2020/"}]}}